2024
Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons
Swartwood N, Li Y, Regan M, Marks S, Barham T, Asay G, Cohen T, Hill A, Horsburgh C, Khan A, McCree D, Myles R, Salomon J, Self J, Menzies N. Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons. JAMA Network Open 2024, 7: e2431988. PMID: 39254977, PMCID: PMC11388029, DOI: 10.1001/jamanetworkopen.2024.31988.Peer-Reviewed Original ResearchConceptsUS-born personsEthnic disparitiesCase-fatality rateTB deathsTB casesTB incidenceSex-adjusted incidenceNational TB surveillance dataTB surveillance dataQuality-adjusted life yearsDistrict of ColumbiaTB disparitiesHealth outcomesEconomic outcomesFuture healthOutcome of TBUS-bornTB outcomesEstimate healthLife yearsSocietal costsTB burdenSocietal perspectiveGeneralized additive regression modelsGoal attainmentImpact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R
2023
Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States
Swartwood N, Testa C, Cohen T, Marks S, Hill A, Beeler Asay G, Cochran J, Cranston K, Randall L, Tibbs A, Horsburgh C, Salomon J, Menzies N. Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States. BMC Medicine 2023, 21: 331. PMID: 37649031, PMCID: PMC10469407, DOI: 10.1186/s12916-023-02785-y.Peer-Reviewed Original ResearchConceptsLatent tuberculosis infectionTB outcomesDistrict of ColumbiaTreatment of LTBIIncremental cost-effectiveness ratioTB incidence rateTuberculosis disease burdenQuality-adjusted life yearsCost-effectiveness ratioPublic health agenciesTB casesTB preventionTB incidenceTuberculosis infectionTB epidemiologyDisease burdenIncidence rateService utilizationAdditional interventionsIncidence projectionsLife yearsDemographic dataSocietal perspectiveHealth agenciesPrevention approaches
2021
The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease
Menzies NA, Shrestha S, Parriott A, Marks SM, Hill AN, Dowdy DW, Shete PB, Cohen T, Salomon JA. The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology 2021, 33: 75-83. PMID: 34669631, PMCID: PMC8633045, DOI: 10.1097/ede.0000000000001418.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh positive predictive valueFuture tuberculosisLatent tuberculosis infection treatmentIncremental costHigher treatment initiationCompletion of treatmentInterferon-gamma releaseQuality-adjusted life yearsTransmission dynamic modelLTBI testingTreatment initiationTreatment acceptanceTuberculosis diseasePrevention servicesPredictive valueTreatment servicesLife yearsTuberculosisInfection treatmentSocietal perspectiveIGRATreatment volumeHealth improvementFuture progression